美股异动丨生物技术公司Abivax盘前涨10.5%，传礼来可能有意收购该公司

Group 1 - The core point of the article is that Abivax's stock price increased by 10.5% to $135.97 amid speculation that Eli Lilly may be interested in acquiring the company [1] - Eli Lilly has not commented on the acquisition rumors, stating that it does not comment on business development activities [1] - Abivax reported positive results from a Phase 3 clinical trial of obefazimod for the treatment of ulcerative colitis in July [1]